A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients
-
- Sailyn Alfonso
- Authors' Affiliations: 1Celestino Hernández Robau Hospital, Villa Clara;
-
- Anet Valdés-Zayas
- 2Center of Molecular Immunology;
-
- Eduardo R. Santiesteban
- 3José R. López Tabranes Hospital, Matanzas;
-
- Yoanna I. Flores
- 4National Institute of Oncology and Radiobiology; and
-
- Fernando Areces
- 4National Institute of Oncology and Radiobiology; and
-
- Maurenis Hernández
- 2Center of Molecular Immunology;
-
- Carmen E. Viada
- 2Center of Molecular Immunology;
-
- Ivis C. Mendoza
- 5National Coordinating Center of Clinical Trials
-
- Pedro P. Guerra
- 5National Coordinating Center of Clinical Trials
-
- Elena García
- 5National Coordinating Center of Clinical Trials
-
- Ramón A. Ortiz
- Authors' Affiliations: 1Celestino Hernández Robau Hospital, Villa Clara;
-
- Ana V. de la Torre
- Authors' Affiliations: 1Celestino Hernández Robau Hospital, Villa Clara;
-
- Meylán Cepeda
- Authors' Affiliations: 1Celestino Hernández Robau Hospital, Villa Clara;
-
- Kirenia Pérez
- 2Center of Molecular Immunology;
-
- Eric Chong
- 2Center of Molecular Immunology;
-
- Ana María Hernández
- 2Center of Molecular Immunology;
-
- Darien Toledo
- 2Center of Molecular Immunology;
-
- Zuyén González
- 2Center of Molecular Immunology;
-
- Zaima Mazorra
- 2Center of Molecular Immunology;
-
- Tania Crombet
- 2Center of Molecular Immunology;
-
- Rolando Pérez
- 2Center of Molecular Immunology;
-
- Ana María Vázquez
- 2Center of Molecular Immunology;
-
- Amparo E. Macías
- 2Center of Molecular Immunology;
Description
<jats:title>Abstract</jats:title> <jats:p>Purpose: Racotumomab-alum is an anti-idiotype vaccine targeting the NeuGcGM3 tumor-associated ganglioside. This clinical trial was conducted to provide a preliminary estimate of efficacy and safety of racotumomab as switch maintenance for patients with advanced non–small cell lung cancer (NSCLC).</jats:p> <jats:p>Experimental design: Patients with stage IIIb/IV NSCLC who have at least stable disease after first-line chemotherapy were randomized 1:1 to racotumomab-alum (5 immunizations every 2 weeks and re-immunizations every 4 weeks) or placebo. Treatment was administered beyond progressive disease, until severe performance status worsening or toxicity. At progression, only five patients per group received further anticancer therapy. The primary endpoint was overall survival (OS).</jats:p> <jats:p>Results: One-hundred and seventy-six patients were randomized to racotumomab-alum (n = 87) and placebo (n = 89). Median OS was 8.23 and 6.80 months, respectively [HR, 0.63; 95% confidence interval (CI), 0.46–0.87; P = 0.004]. Median progression-free survival (PFS) in vaccinated patients was 5.33 versus 3.90 months for placebo (HR, 0.73; 95% CI 0.53–0.99; P = 0.039). The most common adverse events in the racotumomab-alum arm were burning and pain at the injection site, bone pain, and asthenia. A high antibody response of IgM and IgG isotype against the NeuGcGM3 ganglioside was obtained. Hyperimmune sera were able to specifically recognize and kill the NeuGcGM3-expressing L1210 cell line. Patients who developed anti-NeuGcGM3 antibodies capable to bind and kill ≥30% L1210 cells showed longer median survival times.</jats:p> <jats:p>Conclusions: Switch maintenance with racotumomab-alum is an effective and a well-tolerated treatment option for patients with advanced NSCLC. Clin Cancer Res; 20(14); 3660–71. ©2014 AACR.</jats:p>
Journal
-
- Clinical Cancer Research
-
Clinical Cancer Research 20 (14), 3660-3671, 2014-07-14
American Association for Cancer Research (AACR)
- Tweet
Details 詳細情報について
-
- CRID
- 1361137044509279360
-
- ISSN
- 15573265
- 10780432
-
- Data Source
-
- Crossref